SlideShare a Scribd company logo
Gastric Cancer Prognosis and Cell Ratio Factors
Kshivets Oleg Surgery Department, Roshal Hospital, Roshal, Moscow, Russia
P-23
OBJECTIVE: We examined cell ratio factors (CRF) significantly affecting gastric cancer
(EC) patients GCP) survival. CRF - ratio between cancer cells (CC) and blood cells
subpopulations.
METHODS: We analyzed data of 799 consecutive GCP (T1-4N0-2M0) (age=57.1±9.4
years; tumor size=5.4±3.1 cm) radically operated (R0) and monitored in 1975-2022 (m=558,
f=241; total gastrectomies=173, distal gastrectomies=461; proximal gastrectomies=165;
combined gastrectomies=247 with resection of esophagus, pancreas, liver, duodenum,
diaphragm, colon transversum, splenectomy, etc; only surgery-S=624, adjuvant
chemoimmunotherapy-AT=175 (5-FU + thymalin/taktivin); T1=238, T2=220, T3=184,
T4=157; N0=437, N1=109, N2=253, M0=799; G1=222, G2=164, G3=413. Variables selected
for prognosis study were input levels of 45 blood parameters, sex, age, TNMG, cell type,
tumor size. Survival curves were estimated by the Kaplan-Meier method. Differences in
curves between groups of GCP were evaluated using a log-rank test. Multivariate Cox
modeling, discriminant analysis, clustering, SEPATH, Monte Carlo, bootstrap and neural
networks computing were used to determine any significant dependence.
RESULTS: Overall life span (LS) was 2128.9±2300.3 days and cumulative 5-year survival
(5YS) reached 58.4%, 10 years – 51.9%, 20 years – 39%, 30 years – 27.2%. 318 GCP lived
more than 5 years (LS=4304.5±2290.6 days), 169 ECP – more than 10 years
(LS=5919.5±2020 days). 290 GCP died because of GC (LS=651±347.2 days). Cox modeling
displayed that ECP survival significantly depended on CRF: healthy cells/CC,
erythrocytes/CC, monocytes/CC, phase transition (PT) in terms of synergetics early—
invasive cancer; PT N0--N12, age, G1-3, hemorrhage time, ESS, sex, AT, prothrombin
index, residual nitrogen. Neural networks, genetic algorithm selection and bootstrap
simulation revealed relationships between 5YS and PT early—invasive cancer (rank=1);
PT N0--N12 (2); healthy cells/CC (3), erythrocytes/CC (4), thrombocytes/CC (5),
monocytes/CC (6), segmented neutrophils/CC (7), leucocytes/CC (8), lymphocytes/CC (9),
stick neutrophils/CC (10), eosinophils/CC (11). Correct prediction of 5YS was 100% by
neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: GCP survival after radical procedures significantly depended on CRF.
Cox Proportional Hazards
Results, n=799
Parameter
Estimate
Standard
Error
Chi-
square
P value
95%
Lower CL
95%
Upper CL
Hazard
Ratio
ESS -0.012083 0.004865 6.16915 0.013000 -0.021618 -0.002548 0.987990
Hemorrhage Time 0.001295 0.000371 12.20046 0.000478 0.000568 0.002021 1.001296
Residual Nitrogen 0.049233 0.008903 30.58332 0.000000 0.031784 0.066681 1.050465
Prothrombin Idex 0.021321 0.004897 18.95581 0.000013 0.011723 0.030920 1.021550
Age 0.012628 0.006097 4.28971 0.038344 0.000678 0.024577 1.012708
Sex 0.304544 0.122528 6.17776 0.012937 0.064394 0.544694 1.356006
G1-3 0.163023 0.065880 6.12346 0.013340 0.033902 0.292145 1.177064
Procedure Type 0.229288 0.072502 10.00130 0.001564 0.087186 0.371390 1.257704
Adjuvant Treatment -0.518082 0.177398 8.52903 0.003495 -0.865775 -0.170388 0.595662
PhT Early-Invasive Cancer 1.282134 0.239070 28.76183 0.000000 0.813565 1.750703 3.604323
PhT N0---N12 0.453418 0.066399 46.63044 0.000000 0.323278 0.583559 1.573682
Cox Regression B SE Wald df P Exp(B) 95,0% CI
Lower Upper
Erythrocytes/CC ,089 ,039 5,331 1 ,021 1,093 1,014 1,179
Monocytes/CC ,213 ,100 4,548 1 ,033 1,237 1,017 1,505
Healthy Cells/CC -,043 ,012 12,956 1 ,000 ,958 ,936 ,981
Survival Function
GCP=799; 5YS=58.4%;
10YS=52.2%; 20YS=40.3%; 30YS=27.2%.
Complete Censored
-5 0 5 10 15 20 25 30 35 40
Years after Gastrectomies
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1,0
Cumulative
Proportion
Surviving
Cumulative Proportion Surviving (Kaplan-Meier)
Complete Censored
10-Year Survival of Early GCP=88.4%;
10-Year Survival of Invasive GCP=41.5%;
P=0.000 by Log Rank Test.
0 5 10 15 20 25 30 35
Years after Gastrectomies
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1,0
Cumulative
Proportion
Surviving
Invasive GCP
Early GCP
Cumulative Proportion Surviving (Kaplan-Meier)
Complete Censored
10-Year survival GCP N0=69.7%;
10-Year Survival GCP N1-2=29.5%;
P=0.000 by Log Rank.
0 5 10 15 20 25 30 35 40
Years after Gastrectomies
0,0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1,0
Cumulative
Proportion
Surviving
GCP N1-2
GCP N0
Cumulative Proportion Surviving (Kaplan-Meier)
10-Year Survival GCP after AT=59.7%;
10-Year Survival after Surgery=50.6%;
P=0.032 by Log Rank Test.
Complete Censored
0 5 10 15 20 25 30
Years after Gastrectomies
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
Cumulative
Proportion
Surviving
only Surgery
AT
Neural Networks: n=611;
Baseline Error=0.000;
Area under ROC Curve=1.000;
Correct Classification Rate=100%
Rank Sensitivity
Phase Transition Early-Invasive Cancer 1 58263
Phase Transition N0—N12 2 51328
Healthy Cells/Cancer Cells 3 33644
Erythrocytes/Cancer Cells
Thrombocytes/Cancer Cells
Monocytes/Cancer Cells
Segmented Neutrophils/Cancer Cells
Leucocytes/Cancer Cells
Lymphocytes/Cancer Cells
4
5
6
7
8
9
25968
20448
12218
13604
12400
10482
Stick Neutrophils/Cancer Cells
Eosinophils/Cancer Cells
10
11
10002
8630

More Related Content

Similar to • Gastric cancer prognosis and cell ratio factors

Kshivets ny2021aats
Kshivets ny2021aatsKshivets ny2021aats
Kshivets ny2021aats
Oleg Kshivets
 
Kshivets barcelona2017
Kshivets barcelona2017Kshivets barcelona2017
Kshivets barcelona2017
Oleg Kshivets
 
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Oleg Kshivets
 
Kshivets eacts milan2018
Kshivets eacts milan2018Kshivets eacts milan2018
Kshivets eacts milan2018
Oleg Kshivets
 
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Oleg Kshivets
 
Kshivets O. Esophagogastric Cancer Surgery
Kshivets O. Esophagogastric Cancer SurgeryKshivets O. Esophagogastric Cancer Surgery
Kshivets O. Esophagogastric Cancer Surgery
Oleg Kshivets
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Oleg Kshivets
 
Kshivets ASCVTS Moscow2018
Kshivets ASCVTS Moscow2018Kshivets ASCVTS Moscow2018
Kshivets ASCVTS Moscow2018
Oleg Kshivets
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
Oleg Kshivets
 
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer SurgeryKshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
Oleg Kshivets
 
Kshivets Oleg Optimization of Management for Esophageal Cancer Patients (T1-...
Kshivets Oleg  Optimization of Management for Esophageal Cancer Patients (T1-...Kshivets Oleg  Optimization of Management for Esophageal Cancer Patients (T1-...
Kshivets Oleg Optimization of Management for Esophageal Cancer Patients (T1-...
Oleg Kshivets
 
Kshivets esmo2021
Kshivets esmo2021Kshivets esmo2021
Kshivets esmo2021
Oleg Kshivets
 
Kshivets O. Gastric Cancer Relapse Surgery
Kshivets O. Gastric Cancer Relapse SurgeryKshivets O. Gastric Cancer Relapse Surgery
Kshivets O. Gastric Cancer Relapse Surgery
Oleg Kshivets
 
Kshivets milan2014
Kshivets milan2014Kshivets milan2014
Kshivets milan2014
Oleg Kshivets
 
Kshivets IASLC_Vienna2016
Kshivets IASLC_Vienna2016Kshivets IASLC_Vienna2016
Kshivets IASLC_Vienna2016
Oleg Kshivets
 
Kshivets barcelona2016
Kshivets barcelona2016Kshivets barcelona2016
Kshivets barcelona2016
Oleg Kshivets
 
ACUTE MYELOID LEUKEMIA
ACUTE MYELOID LEUKEMIAACUTE MYELOID LEUKEMIA
ACUTE MYELOID LEUKEMIA
flasco_org
 
Kshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfKshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdf
Oleg Kshivets
 
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Oleg Kshivets
 
Kshivets barcelona2020
Kshivets barcelona2020Kshivets barcelona2020
Kshivets barcelona2020
Oleg Kshivets
 

Similar to • Gastric cancer prognosis and cell ratio factors (20)

Kshivets ny2021aats
Kshivets ny2021aatsKshivets ny2021aats
Kshivets ny2021aats
 
Kshivets barcelona2017
Kshivets barcelona2017Kshivets barcelona2017
Kshivets barcelona2017
 
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
 
Kshivets eacts milan2018
Kshivets eacts milan2018Kshivets eacts milan2018
Kshivets eacts milan2018
 
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
Local Advanced Esophageal Cancer (T3-4N0-2M0): Artificial Intelligence, Syner...
 
Kshivets O. Esophagogastric Cancer Surgery
Kshivets O. Esophagogastric Cancer SurgeryKshivets O. Esophagogastric Cancer Surgery
Kshivets O. Esophagogastric Cancer Surgery
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
 
Kshivets ASCVTS Moscow2018
Kshivets ASCVTS Moscow2018Kshivets ASCVTS Moscow2018
Kshivets ASCVTS Moscow2018
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
 
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer SurgeryKshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
 
Kshivets Oleg Optimization of Management for Esophageal Cancer Patients (T1-...
Kshivets Oleg  Optimization of Management for Esophageal Cancer Patients (T1-...Kshivets Oleg  Optimization of Management for Esophageal Cancer Patients (T1-...
Kshivets Oleg Optimization of Management for Esophageal Cancer Patients (T1-...
 
Kshivets esmo2021
Kshivets esmo2021Kshivets esmo2021
Kshivets esmo2021
 
Kshivets O. Gastric Cancer Relapse Surgery
Kshivets O. Gastric Cancer Relapse SurgeryKshivets O. Gastric Cancer Relapse Surgery
Kshivets O. Gastric Cancer Relapse Surgery
 
Kshivets milan2014
Kshivets milan2014Kshivets milan2014
Kshivets milan2014
 
Kshivets IASLC_Vienna2016
Kshivets IASLC_Vienna2016Kshivets IASLC_Vienna2016
Kshivets IASLC_Vienna2016
 
Kshivets barcelona2016
Kshivets barcelona2016Kshivets barcelona2016
Kshivets barcelona2016
 
ACUTE MYELOID LEUKEMIA
ACUTE MYELOID LEUKEMIAACUTE MYELOID LEUKEMIA
ACUTE MYELOID LEUKEMIA
 
Kshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfKshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdf
 
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
 
Kshivets barcelona2020
Kshivets barcelona2020Kshivets barcelona2020
Kshivets barcelona2020
 

More from Oleg Kshivets

Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 
Kshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdfKshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdf
Oleg Kshivets
 
Kshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdfKshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdf
Oleg Kshivets
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
Oleg Kshivets
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
Oleg Kshivets
 
Lung Cancer: Precise Prediction
Lung Cancer: Precise PredictionLung Cancer: Precise Prediction
Lung Cancer: Precise Prediction
Oleg Kshivets
 
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Oleg Kshivets
 
Kshivets elcc2022
Kshivets elcc2022Kshivets elcc2022
Kshivets elcc2022
Oleg Kshivets
 
Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659
Oleg Kshivets
 
Kshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarrKshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarr
Oleg Kshivets
 
Kshivets eso10 y2021
Kshivets eso10 y2021Kshivets eso10 y2021
Kshivets eso10 y2021
Oleg Kshivets
 
Kshivets iaslc denver2021
Kshivets iaslc denver2021Kshivets iaslc denver2021
Kshivets iaslc denver2021
Oleg Kshivets
 
2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets
Oleg Kshivets
 
Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival           Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival
Oleg Kshivets
 
Kshivets iaslc singapore2020
Kshivets iaslc singapore2020Kshivets iaslc singapore2020
Kshivets iaslc singapore2020
Oleg Kshivets
 

More from Oleg Kshivets (15)

Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
Kshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdfKshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdf
 
Kshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdfKshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdf
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
 
Kshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdfKshivets_ELCC2023.pdf
Kshivets_ELCC2023.pdf
 
Lung Cancer: Precise Prediction
Lung Cancer: Precise PredictionLung Cancer: Precise Prediction
Lung Cancer: Precise Prediction
 
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
Lung cancer cell dynamics significantly depended on blood cell circuit, bioch...
 
Kshivets elcc2022
Kshivets elcc2022Kshivets elcc2022
Kshivets elcc2022
 
Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659
 
Kshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarrKshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarr
 
Kshivets eso10 y2021
Kshivets eso10 y2021Kshivets eso10 y2021
Kshivets eso10 y2021
 
Kshivets iaslc denver2021
Kshivets iaslc denver2021Kshivets iaslc denver2021
Kshivets iaslc denver2021
 
2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets
 
Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival           Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival
 
Kshivets iaslc singapore2020
Kshivets iaslc singapore2020Kshivets iaslc singapore2020
Kshivets iaslc singapore2020
 

Recently uploaded

Rice Bran Oil Manufacturing Process
Rice Bran Oil Manufacturing ProcessRice Bran Oil Manufacturing Process
Rice Bran Oil Manufacturing Process
nishurani4455
 
Hemodialysis: Chapter 9, Arteriovenous Fistula and Graft: Basics, Creation, U...
Hemodialysis: Chapter 9, Arteriovenous Fistula and Graft: Basics, Creation, U...Hemodialysis: Chapter 9, Arteriovenous Fistula and Graft: Basics, Creation, U...
Hemodialysis: Chapter 9, Arteriovenous Fistula and Graft: Basics, Creation, U...
NephroTube - Dr.Gawad
 
STAPHYSAGRIA.BHMS.MATERIA MEDICA.HOMOEOPATHY
STAPHYSAGRIA.BHMS.MATERIA MEDICA.HOMOEOPATHYSTAPHYSAGRIA.BHMS.MATERIA MEDICA.HOMOEOPATHY
STAPHYSAGRIA.BHMS.MATERIA MEDICA.HOMOEOPATHY
DRPREETHIJAMESP
 
Drug Repurposing for Parasitic Diseases.pptx
Drug Repurposing for Parasitic Diseases.pptxDrug Repurposing for Parasitic Diseases.pptx
Drug Repurposing for Parasitic Diseases.pptx
drebrahiim
 
SA Gastro Cure(pancreatic cancer treatment in india).pptx
SA Gastro Cure(pancreatic cancer treatment in india).pptxSA Gastro Cure(pancreatic cancer treatment in india).pptx
SA Gastro Cure(pancreatic cancer treatment in india).pptx
VinothKumar70905
 
How to Relieve Prostate Congestion- Here are some Effective Strategies.pptx
How to Relieve Prostate Congestion- Here are some Effective Strategies.pptxHow to Relieve Prostate Congestion- Here are some Effective Strategies.pptx
How to Relieve Prostate Congestion- Here are some Effective Strategies.pptx
AmandaChou9
 
OBSTETRICS SEPSIS - BUNDLE APPROACH.pptx
OBSTETRICS SEPSIS - BUNDLE APPROACH.pptxOBSTETRICS SEPSIS - BUNDLE APPROACH.pptx
OBSTETRICS SEPSIS - BUNDLE APPROACH.pptx
Niranjan Chavan
 
2nd week of Human development .embryology
2nd week of Human development .embryology2nd week of Human development .embryology
2nd week of Human development .embryology
Mithilesh Chaurasia
 
STRATEGIES FOR RATIONALISING/REDUCING CAESAREAN SECTION RATE BY USE OF "SION ...
STRATEGIES FOR RATIONALISING/REDUCING CAESAREAN SECTION RATE BY USE OF "SION ...STRATEGIES FOR RATIONALISING/REDUCING CAESAREAN SECTION RATE BY USE OF "SION ...
STRATEGIES FOR RATIONALISING/REDUCING CAESAREAN SECTION RATE BY USE OF "SION ...
Niranjan Chavan
 
Hemodialysis: Chapter 11, Venous Catheter - Basics, Insertion, Use and Care -...
Hemodialysis: Chapter 11, Venous Catheter - Basics, Insertion, Use and Care -...Hemodialysis: Chapter 11, Venous Catheter - Basics, Insertion, Use and Care -...
Hemodialysis: Chapter 11, Venous Catheter - Basics, Insertion, Use and Care -...
NephroTube - Dr.Gawad
 
THE MANAGEMENT OF PROSTATE CANCER . pptx
THE MANAGEMENT OF PROSTATE CANCER . pptxTHE MANAGEMENT OF PROSTATE CANCER . pptx
THE MANAGEMENT OF PROSTATE CANCER . pptx
Bright Chipili
 
Article - Design and evaluation of novel inhibitors for the treatment of clea...
Article - Design and evaluation of novel inhibitors for the treatment of clea...Article - Design and evaluation of novel inhibitors for the treatment of clea...
Article - Design and evaluation of novel inhibitors for the treatment of clea...
Trustlife
 
Safeguarding Reproductive Health- Preventing Fallopian Tube Blockage After a ...
Safeguarding Reproductive Health- Preventing Fallopian Tube Blockage After a ...Safeguarding Reproductive Health- Preventing Fallopian Tube Blockage After a ...
Safeguarding Reproductive Health- Preventing Fallopian Tube Blockage After a ...
FFragrant
 
Prevention of Cruelty to animals act 1960
Prevention of Cruelty to animals act 1960Prevention of Cruelty to animals act 1960
Prevention of Cruelty to animals act 1960
PratibhaSonawane5
 
NUTRICONNECT NEWSLETTER 3RD ISSUE 2ND VOLUME.pdf
NUTRICONNECT NEWSLETTER 3RD ISSUE 2ND VOLUME.pdfNUTRICONNECT NEWSLETTER 3RD ISSUE 2ND VOLUME.pdf
NUTRICONNECT NEWSLETTER 3RD ISSUE 2ND VOLUME.pdf
MatsikoAlex
 
medical law and ethics presentation .ppt
medical law and ethics presentation .pptmedical law and ethics presentation .ppt
medical law and ethics presentation .ppt
PseudoPocket
 
Hand Book of Oncology Nursing - Cancer Nursing Book
Hand Book of Oncology Nursing - Cancer Nursing BookHand Book of Oncology Nursing - Cancer Nursing Book
Hand Book of Oncology Nursing - Cancer Nursing Book
BP KOIRALA INSTITUTE OF HELATH SCIENCS,, NEPAL
 
anthelmintic-drugs.pptx pharmacology dep
anthelmintic-drugs.pptx pharmacology depanthelmintic-drugs.pptx pharmacology dep
anthelmintic-drugs.pptx pharmacology dep
sapnasirswal
 
ONYDA XR clonidine liquid preparation by Dr. Amrutha
ONYDA XR clonidine liquid preparation by Dr. AmruthaONYDA XR clonidine liquid preparation by Dr. Amrutha
ONYDA XR clonidine liquid preparation by Dr. Amrutha
Amrutha Gudimetla
 
Bangalore @Girls @Call WhatsApp Numbers 🫦0000XX0000🫦 List For Friendship Girl...
Bangalore @Girls @Call WhatsApp Numbers 🫦0000XX0000🫦 List For Friendship Girl...Bangalore @Girls @Call WhatsApp Numbers 🫦0000XX0000🫦 List For Friendship Girl...
Bangalore @Girls @Call WhatsApp Numbers 🫦0000XX0000🫦 List For Friendship Girl...
paridubey2024#G05
 

Recently uploaded (20)

Rice Bran Oil Manufacturing Process
Rice Bran Oil Manufacturing ProcessRice Bran Oil Manufacturing Process
Rice Bran Oil Manufacturing Process
 
Hemodialysis: Chapter 9, Arteriovenous Fistula and Graft: Basics, Creation, U...
Hemodialysis: Chapter 9, Arteriovenous Fistula and Graft: Basics, Creation, U...Hemodialysis: Chapter 9, Arteriovenous Fistula and Graft: Basics, Creation, U...
Hemodialysis: Chapter 9, Arteriovenous Fistula and Graft: Basics, Creation, U...
 
STAPHYSAGRIA.BHMS.MATERIA MEDICA.HOMOEOPATHY
STAPHYSAGRIA.BHMS.MATERIA MEDICA.HOMOEOPATHYSTAPHYSAGRIA.BHMS.MATERIA MEDICA.HOMOEOPATHY
STAPHYSAGRIA.BHMS.MATERIA MEDICA.HOMOEOPATHY
 
Drug Repurposing for Parasitic Diseases.pptx
Drug Repurposing for Parasitic Diseases.pptxDrug Repurposing for Parasitic Diseases.pptx
Drug Repurposing for Parasitic Diseases.pptx
 
SA Gastro Cure(pancreatic cancer treatment in india).pptx
SA Gastro Cure(pancreatic cancer treatment in india).pptxSA Gastro Cure(pancreatic cancer treatment in india).pptx
SA Gastro Cure(pancreatic cancer treatment in india).pptx
 
How to Relieve Prostate Congestion- Here are some Effective Strategies.pptx
How to Relieve Prostate Congestion- Here are some Effective Strategies.pptxHow to Relieve Prostate Congestion- Here are some Effective Strategies.pptx
How to Relieve Prostate Congestion- Here are some Effective Strategies.pptx
 
OBSTETRICS SEPSIS - BUNDLE APPROACH.pptx
OBSTETRICS SEPSIS - BUNDLE APPROACH.pptxOBSTETRICS SEPSIS - BUNDLE APPROACH.pptx
OBSTETRICS SEPSIS - BUNDLE APPROACH.pptx
 
2nd week of Human development .embryology
2nd week of Human development .embryology2nd week of Human development .embryology
2nd week of Human development .embryology
 
STRATEGIES FOR RATIONALISING/REDUCING CAESAREAN SECTION RATE BY USE OF "SION ...
STRATEGIES FOR RATIONALISING/REDUCING CAESAREAN SECTION RATE BY USE OF "SION ...STRATEGIES FOR RATIONALISING/REDUCING CAESAREAN SECTION RATE BY USE OF "SION ...
STRATEGIES FOR RATIONALISING/REDUCING CAESAREAN SECTION RATE BY USE OF "SION ...
 
Hemodialysis: Chapter 11, Venous Catheter - Basics, Insertion, Use and Care -...
Hemodialysis: Chapter 11, Venous Catheter - Basics, Insertion, Use and Care -...Hemodialysis: Chapter 11, Venous Catheter - Basics, Insertion, Use and Care -...
Hemodialysis: Chapter 11, Venous Catheter - Basics, Insertion, Use and Care -...
 
THE MANAGEMENT OF PROSTATE CANCER . pptx
THE MANAGEMENT OF PROSTATE CANCER . pptxTHE MANAGEMENT OF PROSTATE CANCER . pptx
THE MANAGEMENT OF PROSTATE CANCER . pptx
 
Article - Design and evaluation of novel inhibitors for the treatment of clea...
Article - Design and evaluation of novel inhibitors for the treatment of clea...Article - Design and evaluation of novel inhibitors for the treatment of clea...
Article - Design and evaluation of novel inhibitors for the treatment of clea...
 
Safeguarding Reproductive Health- Preventing Fallopian Tube Blockage After a ...
Safeguarding Reproductive Health- Preventing Fallopian Tube Blockage After a ...Safeguarding Reproductive Health- Preventing Fallopian Tube Blockage After a ...
Safeguarding Reproductive Health- Preventing Fallopian Tube Blockage After a ...
 
Prevention of Cruelty to animals act 1960
Prevention of Cruelty to animals act 1960Prevention of Cruelty to animals act 1960
Prevention of Cruelty to animals act 1960
 
NUTRICONNECT NEWSLETTER 3RD ISSUE 2ND VOLUME.pdf
NUTRICONNECT NEWSLETTER 3RD ISSUE 2ND VOLUME.pdfNUTRICONNECT NEWSLETTER 3RD ISSUE 2ND VOLUME.pdf
NUTRICONNECT NEWSLETTER 3RD ISSUE 2ND VOLUME.pdf
 
medical law and ethics presentation .ppt
medical law and ethics presentation .pptmedical law and ethics presentation .ppt
medical law and ethics presentation .ppt
 
Hand Book of Oncology Nursing - Cancer Nursing Book
Hand Book of Oncology Nursing - Cancer Nursing BookHand Book of Oncology Nursing - Cancer Nursing Book
Hand Book of Oncology Nursing - Cancer Nursing Book
 
anthelmintic-drugs.pptx pharmacology dep
anthelmintic-drugs.pptx pharmacology depanthelmintic-drugs.pptx pharmacology dep
anthelmintic-drugs.pptx pharmacology dep
 
ONYDA XR clonidine liquid preparation by Dr. Amrutha
ONYDA XR clonidine liquid preparation by Dr. AmruthaONYDA XR clonidine liquid preparation by Dr. Amrutha
ONYDA XR clonidine liquid preparation by Dr. Amrutha
 
Bangalore @Girls @Call WhatsApp Numbers 🫦0000XX0000🫦 List For Friendship Girl...
Bangalore @Girls @Call WhatsApp Numbers 🫦0000XX0000🫦 List For Friendship Girl...Bangalore @Girls @Call WhatsApp Numbers 🫦0000XX0000🫦 List For Friendship Girl...
Bangalore @Girls @Call WhatsApp Numbers 🫦0000XX0000🫦 List For Friendship Girl...
 

• Gastric cancer prognosis and cell ratio factors

  • 1. Gastric Cancer Prognosis and Cell Ratio Factors Kshivets Oleg Surgery Department, Roshal Hospital, Roshal, Moscow, Russia P-23 OBJECTIVE: We examined cell ratio factors (CRF) significantly affecting gastric cancer (EC) patients GCP) survival. CRF - ratio between cancer cells (CC) and blood cells subpopulations. METHODS: We analyzed data of 799 consecutive GCP (T1-4N0-2M0) (age=57.1±9.4 years; tumor size=5.4±3.1 cm) radically operated (R0) and monitored in 1975-2022 (m=558, f=241; total gastrectomies=173, distal gastrectomies=461; proximal gastrectomies=165; combined gastrectomies=247 with resection of esophagus, pancreas, liver, duodenum, diaphragm, colon transversum, splenectomy, etc; only surgery-S=624, adjuvant chemoimmunotherapy-AT=175 (5-FU + thymalin/taktivin); T1=238, T2=220, T3=184, T4=157; N0=437, N1=109, N2=253, M0=799; G1=222, G2=164, G3=413. Variables selected for prognosis study were input levels of 45 blood parameters, sex, age, TNMG, cell type, tumor size. Survival curves were estimated by the Kaplan-Meier method. Differences in curves between groups of GCP were evaluated using a log-rank test. Multivariate Cox modeling, discriminant analysis, clustering, SEPATH, Monte Carlo, bootstrap and neural networks computing were used to determine any significant dependence. RESULTS: Overall life span (LS) was 2128.9±2300.3 days and cumulative 5-year survival (5YS) reached 58.4%, 10 years – 51.9%, 20 years – 39%, 30 years – 27.2%. 318 GCP lived more than 5 years (LS=4304.5±2290.6 days), 169 ECP – more than 10 years (LS=5919.5±2020 days). 290 GCP died because of GC (LS=651±347.2 days). Cox modeling displayed that ECP survival significantly depended on CRF: healthy cells/CC, erythrocytes/CC, monocytes/CC, phase transition (PT) in terms of synergetics early— invasive cancer; PT N0--N12, age, G1-3, hemorrhage time, ESS, sex, AT, prothrombin index, residual nitrogen. Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early—invasive cancer (rank=1); PT N0--N12 (2); healthy cells/CC (3), erythrocytes/CC (4), thrombocytes/CC (5), monocytes/CC (6), segmented neutrophils/CC (7), leucocytes/CC (8), lymphocytes/CC (9), stick neutrophils/CC (10), eosinophils/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0). CONCLUSIONS: GCP survival after radical procedures significantly depended on CRF. Cox Proportional Hazards Results, n=799 Parameter Estimate Standard Error Chi- square P value 95% Lower CL 95% Upper CL Hazard Ratio ESS -0.012083 0.004865 6.16915 0.013000 -0.021618 -0.002548 0.987990 Hemorrhage Time 0.001295 0.000371 12.20046 0.000478 0.000568 0.002021 1.001296 Residual Nitrogen 0.049233 0.008903 30.58332 0.000000 0.031784 0.066681 1.050465 Prothrombin Idex 0.021321 0.004897 18.95581 0.000013 0.011723 0.030920 1.021550 Age 0.012628 0.006097 4.28971 0.038344 0.000678 0.024577 1.012708 Sex 0.304544 0.122528 6.17776 0.012937 0.064394 0.544694 1.356006 G1-3 0.163023 0.065880 6.12346 0.013340 0.033902 0.292145 1.177064 Procedure Type 0.229288 0.072502 10.00130 0.001564 0.087186 0.371390 1.257704 Adjuvant Treatment -0.518082 0.177398 8.52903 0.003495 -0.865775 -0.170388 0.595662 PhT Early-Invasive Cancer 1.282134 0.239070 28.76183 0.000000 0.813565 1.750703 3.604323 PhT N0---N12 0.453418 0.066399 46.63044 0.000000 0.323278 0.583559 1.573682 Cox Regression B SE Wald df P Exp(B) 95,0% CI Lower Upper Erythrocytes/CC ,089 ,039 5,331 1 ,021 1,093 1,014 1,179 Monocytes/CC ,213 ,100 4,548 1 ,033 1,237 1,017 1,505 Healthy Cells/CC -,043 ,012 12,956 1 ,000 ,958 ,936 ,981 Survival Function GCP=799; 5YS=58.4%; 10YS=52.2%; 20YS=40.3%; 30YS=27.2%. Complete Censored -5 0 5 10 15 20 25 30 35 40 Years after Gastrectomies 0,1 0,2 0,3 0,4 0,5 0,6 0,7 0,8 0,9 1,0 Cumulative Proportion Surviving Cumulative Proportion Surviving (Kaplan-Meier) Complete Censored 10-Year Survival of Early GCP=88.4%; 10-Year Survival of Invasive GCP=41.5%; P=0.000 by Log Rank Test. 0 5 10 15 20 25 30 35 Years after Gastrectomies 0,3 0,4 0,5 0,6 0,7 0,8 0,9 1,0 Cumulative Proportion Surviving Invasive GCP Early GCP Cumulative Proportion Surviving (Kaplan-Meier) Complete Censored 10-Year survival GCP N0=69.7%; 10-Year Survival GCP N1-2=29.5%; P=0.000 by Log Rank. 0 5 10 15 20 25 30 35 40 Years after Gastrectomies 0,0 0,1 0,2 0,3 0,4 0,5 0,6 0,7 0,8 0,9 1,0 Cumulative Proportion Surviving GCP N1-2 GCP N0 Cumulative Proportion Surviving (Kaplan-Meier) 10-Year Survival GCP after AT=59.7%; 10-Year Survival after Surgery=50.6%; P=0.032 by Log Rank Test. Complete Censored 0 5 10 15 20 25 30 Years after Gastrectomies 0,1 0,2 0,3 0,4 0,5 0,6 0,7 0,8 Cumulative Proportion Surviving only Surgery AT Neural Networks: n=611; Baseline Error=0.000; Area under ROC Curve=1.000; Correct Classification Rate=100% Rank Sensitivity Phase Transition Early-Invasive Cancer 1 58263 Phase Transition N0—N12 2 51328 Healthy Cells/Cancer Cells 3 33644 Erythrocytes/Cancer Cells Thrombocytes/Cancer Cells Monocytes/Cancer Cells Segmented Neutrophils/Cancer Cells Leucocytes/Cancer Cells Lymphocytes/Cancer Cells 4 5 6 7 8 9 25968 20448 12218 13604 12400 10482 Stick Neutrophils/Cancer Cells Eosinophils/Cancer Cells 10 11 10002 8630